Clinical trials: Pulmonary Artery Hypertension
Hypertension, Pulmonary
An Observational Study For Ambrisentan
The purpose of the programme is to collect safety data on ambrisentan when used in clinical practice
- Trial name
- VOLT (NCT00679224)
- Testing
- ambrisentan
- Where
- 112 sites in Australia, Belgium and 13 more
- Volunteers
- 800 people
- Sponsor
- GlaxoSmithKline
Pulmonary Arterial Hypertension (PAH), Exercise Therapy
PAH Exercise Study
Ten patients with PAH who are stable and eligible to initiate sotatercept therapy will participate in a 26 week study that consists of a 24-week intervention period where patients will receive complimentary sotatercept as…
- Trial name
- NCT06941441
- Testing
- Home exercise program
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Washington
Hypertension, Pulmonary
Drug Use Investigation for VOLIBRIS® (Ambrisentan) (Pulmonary Arterial Hypertension)
The objective of this post-marketing surveillance study is to evaluate the incidence of adverse events in Japanese subjects with pulmonary arterial hypertension treated with ambrisentan basd on prescribing information under the…
- Trial name
- NCT01406327
- Testing
- Ambrisentan
- Volunteers
- 900 people
- Sponsor
- GlaxoSmithKline
Pulmonary Hypertension
Pulmonary Artery DenerVation Clinical Study Using the Gradient Denervation System in Heart Failure Patients With Pulmonary Hypertension Group 2 (PreVail-PH2 OUS Study)
Characterize the impact of pulmonary artery denervation on the quality of life in Heart Failure Patients with Group 2 Pulmonary Hypertension
- Trial name
- PreVailPH2 OUS (NCT06495970)
- Testing
- Gradient Denervation System
- Where
- 3 sites in Spain
- Volunteers
- 20 people
- Sponsor
- Gradient Denervation Technologies
Pulmonary Arterial Hypertension
Comparative Bioavailability of Treprostinil Diethanolamine Manufactured by Two Independent Facilities
The purpose of this study is to compare the bioavailability of a single 1mg dose of treprostinil diethanolamine sustained release (SR) tablets manufactured by two independent facilities.
- Trial name
- NCT01165476
- Testing
- Treprostinil diethanolamine
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- United Therapeutics
Pulmonary Hypertension
Phase 1/1b Study With Nab-sirolimus for Patients With Severe Pulmonary Arterial Hypertension
mTOR activation has been shown to be relevant in the development and progression of pulmonary hypertension. Inhibition of mTOR has been shown to reverse or regress pulmonary hypertension in animal models.
- Trial name
- NCT02587325
- Testing
- nab-sirolimus
- Where
- 6 sites in United States
- Volunteers
- 15 people
- Sponsor
- Aadi Bioscience, Inc.
Heart Diseases, Hypertension, Pulmonary
Study of the Efficacy and Safety of Tezosentan in Patients With Pre-operative Pulmonary Hypertension, Due to Left Heart Disease, Undergoing Open Heart Surgery
Endothelin-1 is a powerful substance that may be involved in causing hemodynamic instability (problems related to unstable blood pressure) during and after open heart surgery.
- Trial name
- NCT00458276
- Testing
- tezosentan
- Where
- 33 sites in United States, Austria and 12 more
- Volunteers
- 274 people
- Sponsor
- Idorsia Pharmaceuticals Ltd.
Systemic Lupus Erythematosus, Pulmonary Arterial Hypertension
Anti-CD20 Antibodies for Treatment of SLE-PAH
This is a prospective, single-arm, single-center, explorative clinical trial to evaluate the effect of Rituximab on disease progression in subjects with SLE-PAH receiving concurrent stable-dose standard medical therapy.
- Trial name
- NCT05828147
- Testing
- Rituximab
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Chinese SLE Treatment And Research Group
Anesthesia, Pulmonary Hypertension
Effect of Vasopressin Versus Norepinephrine on Post-operative Mean Pulmonary Arterial Pressure Following Pulmonary Endarterectomy Surgery,
Chronic thromboembolic pulmonary hypertension (CTEPH), one of the leading causes of pulmonary hypertension (PH), is caused by the chronic obstruction of the pulmonary arteries following episode of pulmonary embolism.
- Conditions
- Anesthesia, Pulmonary Hypertension, Chronic Pulmonary Thromboembolism, Vasopressor
- Trial name
- VANOPE (NCT07614438)
- Testing
- Vasopressin, Norepinephrine
- Where
- France
- Volunteers
- 90 people
- Sponsor
- Fondation Hôpital Saint-Joseph
Pulmonary Arterial Hypertension
LenusPro Pump in PAH Treated With Treprostinil
Subcutaneous treprostinil is used to treat pulmonary arterial hypertension (PAH). Due to local pain it causes a deterioration of quality of life or even abandonment of treatment.
- Trial name
- NCT02889315
- Where
- Poland
- Volunteers
- 20 people
- Sponsor
- Department of Pulmonary Circulation and Thromboembolic Diseases, Medical Center for Postgraduate Med
Coronary Artery Disease, Cerebral Vascular Disease
Pilot Study: Cardiovascular Events in High Risk Orthopedic Surgical Patients
This is a non-randomized, non-interventional pilot observational study designed to follow high-risk patients through their surgical and hospital stay.
- Conditions
- Coronary Artery Disease, Cerebral Vascular Disease, Peripheral Artery Disease, Renal Insufficiency
- Trial name
- NCT01809730
- Where
- United States
- Sponsor
- NYU Langone Health
Pulmonary Arterial Hypertension
Study to Assess the Safety, Tolerability and Pharmacokinetics (PK) of MK-8892 in Participants With Pulmonary Arterial Hypertension (PAH) (MK-8892-005)
This study will evaluate the safety, tolerability, and PK of MK-8892 in participants with pulmonary arterial hypertension. The primary hypothesis is that the geometric mean of MK-8892 area under the concentration time-curve from…
- Trial name
- NCT01926509
- Testing
- MK-8892
- Volunteers
- 23 people
- Sponsor
- Merck Sharp & Dohme LLC
Arterial Pulmonary Hypertension (PAH)
Efficacy and Safety of Triple-targeted Drug Therapy in Treatment-naive Patients With Non-low-risk PAH: A Real-world, Multicenter Study
This study is a multicenter, prospective, observational study aimed at investigating the efficacy and safety of triple targeted drug therapy in patients with arterial pulmonary hypertension (PAH) who are not at low risk and are…
- Trial name
- NCT06753981
- Testing
- Endothelin receptor antagonist (ERA) combined with PDE5i/sGC agonist dual therapy prostacyclin drugs
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Qianfoshan Hospital
Rheumatoid Arthritis, Ankylosing Spondylitis
PatientSpot Formerly Known as ArthritisPower
Patient Power is a patient research network and database (registry) to collect prospective information about demographics, self-reported diagnoses and medications, and willingness to participate in research from participants with…
- Conditions
- Rheumatoid Arthritis, Ankylosing Spondylitis, Fibromyalgia, Gout
- Trial name
- NCT03840928
- Where
- United States
- Volunteers
- 40,000 people, healthy volunteers welcome
- Sponsor
- Global Healthy Living Foundation
Pulmonary Arterial Hypertension
Patient Global Impression Questions for Activity-Induced Symptoms in Participants With PAH
This is an observational, multicenter, single-day, Phase 2 study. This study will include a 14-day Screening Period and Study Day 1 clinic visit.
- Trial name
- PRN (NCT03888365)
- Testing
- Treprostinil, Non-Treprostinil PAH Medications
- Where
- 10 sites in United States
- Volunteers
- 43 people
- Sponsor
- United Therapeutics
Pulmonary Hypertension
Smoking: a Risk Factor for Pulmonary Arterial Hypertension?
Environmental factors may play a role in the genesis of pulmonary hypertension, especially in endothelial dysfunction. One widespread environmental factor associated with systemic endothelial dysfunction is cigarette smoke.
- Trial name
- DACH (NCT01484899)
- Where
- 9 sites in Austria, Germany and 1 more
- Volunteers
- 500 people
- Sponsor
- University of Zurich
Primary and Secondary Pulmonary Hypertension
Efficacy of Type-5 Phosphodiesterase Inhibitors in Primary and Secondary Pulmonary Hypertension
The aim of this trial is to evaluate the efficacy of type-5 phosphodiesterase inhibitors (sildenafil) in primary and secondary pulmonary hypertension
- Trial name
- NCT00155714
- Testing
- type-5 phosphodiesterase Inhibitor (Sildenafil)
- Where
- Taiwan
- Volunteers
- 20 people
- Sponsor
- National Taiwan University Hospital
Pulmonary Arterial Hypertension
Safety Study Extension of Iloprost Power 15 in Pulmonary Arterial Hypertension
Patients with symptomatic idiopathic (IPAH) or familial (FPAH) pulmonary arterial hypertension in New York Heart Association (NYHA) class II to IV , naive to PAH treatment or currently being treated with a stable dose of either…
- Trial name
- PROWESS 15 Ext (NCT00709098)
- Testing
- iloprost
- Where
- 34 sites in United States, Austria and 1 more
- Volunteers
- 49 people
- Sponsor
- Actelion
Healthy Volunteer
A Healthy Volunteer Study Evaluating the the Safety, Tolerability, and Pharmacokinetics of RT234
The objective of this two part study was to demonstrate safety, tolerability, and pharmacokinetics of RT234 in healthy volunteers.
- Trial name
- NCT05567367
- Testing
- Drug: RT234 - vardenafil inhalation powder; Device: RS01 dry powder inhaler (RS01 DPI), Vardenafil Oral Tablet
- Where
- Australia
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Respira Therapeutics, Inc.
Pulmonary Arterial Hypertension, Exercise Associated Pulmonary Arterial Hypertension
Angiogenic Imaging in Pulmonary Arterial Hypertension
Pulmonary arterial hypertension (PAH) is a disorder of elevated pulmonary vascular resistance characterized by progressive remodeling and obliteration of vessels of the distal pulmonary circulation.
- Trial name
- AIPAH (NCT03166306)
- Testing
- PET-CT Imaging with [89Zr]-bevacizumab
- Where
- United States
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- Brigham and Women's Hospital